GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cleo Diagnostics Ltd (ASX:COV) » Definitions » General and Admin. Expense

Cleo Diagnostics (ASX:COV) General and Admin. Expense : A$ Mil (TTM As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Cleo Diagnostics General and Admin. Expense?

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. Cleo Diagnostics's General and Admin. Expense for the six months ended in Dec. 2023 was A$0.40 Mil. Cleo Diagnostics does not have enough years/quarters to calculate the General and Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2023.


Cleo Diagnostics General and Admin. Expense Historical Data

The historical data trend for Cleo Diagnostics's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cleo Diagnostics General and Admin. Expense Chart

Cleo Diagnostics Annual Data
Trend Jun23
General and Admin. Expense
1.10

Cleo Diagnostics Semi-Annual Data
Dec22 Jun23 Dec23
General and Admin. Expense 0.23 0.86 0.40

Cleo Diagnostics General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.


Cleo Diagnostics General and Admin. Expense Related Terms

Thank you for viewing the detailed overview of Cleo Diagnostics's General and Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Cleo Diagnostics (ASX:COV) Business Description

Traded in Other Exchanges
N/A
Address
480 Collins Street, Level 2, Melbourne, VIC, AUS, 3000
Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The Company's first product to market is intended to be the Triage Test which has to date produced strong results to accurately differentiate patients with malignant ovarian cancer from those with benign gynaecological conditions. The Company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer.

Cleo Diagnostics (ASX:COV) Headlines

No Headlines